N-BPs |
Bone selectivity, inexpensive, longtime use, apoptosis of osteoclasts inductors (but don’t eliminate them) |
Effects on renal functions, atypical femoral fractures (osteonecrosis of the jaw), GI adverse effect, acute phase reactions |
Denosumab |
No effect on renal function, low frequency of administration, no bone accumulation, reversible effects |
No bone selectivity, atypical femoral fractures, increased risk of infections, parenteral administration, reduction in bone formation, rebound bone resorption |